This analytical review is devoted to analysis of discrepancies between new American and European recommendations/Significance of level of cardiovascular risk, taget levels of lipids, intensity of therapy, application of therapy with statins and/or expedience of the use of other lipid lowering drugs. Main differences between two recommendations and their similarities are summarized in a table. Schematic representation of suggested consensus on treatment of dyslipidemia with consideration of both recommendations is given in a separate part.